| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CLINICAL PRACTICE GUIDELINE |
University of Colorado at Denver and Health Sciences Center (M.E.W.), Aurora, Colorado 80010; University of British Columbia (R.B.), Vancouver, Canada V6T 1Z4; Alfred Hospital/Monash University (S.R.D.), Melbourne, Victoria 3181, Australia; Mayo Clinic (S.K.), Rochester, Minnesota 55905; Massachusetts General Hospital (K.K.M.), Boston, Massachusetts 02114; St. Luke’s/Roosevelt Hospital Center (W.R.), New York, New York 10019; and Albert Einstein College of Medicine (N.S.), Bronx, New York 10461
Objective: The objective was to provide guidelines for the therapeutic use of androgens in women.
Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.
Evidence: The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. The strength of a recommendation is indicated by the number 1 (strong recommendation, associated with the phrase "we recommend") or 2 (weak recommendation, associated with the phrase "we suggest"). The quality of the evidence is indicated by cross-filled circles, such that 
denotes very-low-quality evidence, low quality, moderate quality, and high quality. Each recommendation is followed by a description of the evidence.
Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society’s CGS, Clinical Affairs Committee (CAC), and Executive Committee. The version approved by the CGS and CAC was placed on The Endocrine Society’s web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes.
Conclusions: We recommend against making a diagnosis of androgen deficiency in women at present because of the lack of a well-defined clinical syndrome and normative data on total or free testosterone levels across the lifespan that can be used to define the disorder. Although there is evidence for short-term efficacy of testosterone in selected populations, such as surgically menopausal women, we recommend against the generalized use of testosterone by women because the indications are inadequate and evidence of safety in long-term studies is lacking. A review of the data currently available is presented, and areas of future research are outlined. To formulate clinical guidelines for use of testosterone in women, additional information will be necessary. This includes defining conditions that, when not treated with androgens, have adverse health consequences to women; defining clinical and laboratory parameters that distinguish those with these conditions; and assessing the efficacy and long-term safety of androgen administration on outcomes that are important to women diagnosed with these conditions. This necessary clinical research cannot occur until the biological, physiological, and psychological underpinnings of the role of androgens in women and candidate disorders are further elucidated.
This article has been cited by other articles:
 |
|
 |
|
  M. Hickey, M. Ambekar, and I. Hammond Should the ovaries be removed or retained at the time of hysterectomy for benign disease? Hum. Reprod. Update, September 30, 2009; (2009) dmp037v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Ebinger, C Sievers, D Ivan, H. Schneider, and G. Stalla Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? J Psychopharmacol, September 1, 2009; 23(7): 841 - 853. [Abstract] [PDF]
|
|
|
|
 |
|
 M.F.R. Sowers, H. Zheng, D. McConnell, B. Nan, C.A. Karvonen-Gutierrez, and J.F. Randolph Jr Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging Hum. Reprod., September 1, 2009; 24(9): 2276 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Vesper and L. M. Thienpont Traceability in Laboratory Medicine Clin. Chem., June 1, 2009; 55(6): 1067 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hickey, M. Peate, C.M. Saunders, and M. Friedlander Breast cancer in young women and its impact on reproductive function Hum. Reprod. Update, May 1, 2009; 15(3): 323 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M Chapman, R. Visvanathan, A. J Hammond, J. E Morley, J. B. Field, K. Tai, D. P Belobrajdic, R. Y. Chen, and M. Horowitz Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women Am. J. Clinical Nutrition, March 1, 2009; 89(3): 880 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Marnach and P. M. Casey Understanding Women's Sexual Health: A Case-Based Approach Mayo Clin. Proc., December 1, 2008; 83(12): 1382 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Davis, M. Moreau, R. Kroll, C. Bouchard, N. Panay, M. Gass, G. D. Braunstein, A. L. Hirschberg, C. Rodenberg, S. Pack, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen N. Engl. J. Med., November 6, 2008; 359(19): 2005 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Yarrow, C. F. Conover, A. V. Purandare, A. M. Bhakta, N. Zheng, B. Conrad, M. K. Altman, S. E. Franz, T. J. Wronski, and S. E. Borst Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1213 - E1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer Ann. Onc., October 1, 2008; 19(10): 1669 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Shufelt and G. D Braunstein Testosterone and the breast Menopause Int, September 1, 2008; 14(3): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Barbieri Update in Female Reproduction: A Life-Cycle Approach J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2439 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Basson Testosterone Supplementation to Improve Women's Sexual Satisfaction: Complexities and Unknowns Ann Intern Med, April 15, 2008; 148(8): 620 - 621. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Martin, R. J. Chang, D. A. Ehrmann, L. Ibanez, R. A. Lobo, R. L. Rosenfield, J. Shapiro, V. M. Montori, and B. A. Swiglo Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1105 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Elaut, G. De Cuypere, P. De Sutter, L. Gijs, M. Van Trotsenburg, G. Heylens, J.-M. Kaufman, R. Rubens, and G. T'Sjoen Hypoactive sexual desire in transsexual women: prevalence and association with testosterone levels Eur. J. Endocrinol., March 1, 2008; 158(3): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt, M. de Andrade, and L. J. Melton III Increased risk of parkinsonism in women who underwent oophorectomy before menopause Neurology, January 15, 2008; 70(3): 200 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Roy, M. Alevizaki, and I. Huhtaniemi In vitro bioassays for androgens and their diagnostic applications Hum. Reprod. Update, January 1, 2008; 14(1): 73 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Braunstein The Endocrine Society Clinical Practice Guideline and The North American Menopause Society Position Statement on Androgen Therapy in Women: Another One of Yogi's Forks J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4091 - 4093. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt, M. de Andrade, and L. J. Melton III Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause Neurology, September 11, 2007; 69(11): 1074 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Ganz and G. A. Greendale Female Sexual Desire--Beyond Testosterone J Natl Cancer Inst, May 2, 2007; 99(9): 659 - 661. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Roberts Managing the menopause BMJ, April 7, 2007; 334(7596): 736 - 741. [Full Text] [PDF]
|
|
|
|
|
|
W. Rosner, R. J. Auchus, R. Azziz, P. M. Sluss, and H. Raff Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 405 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Practice Guideline: When Is Androgen Therapy Indicated for Women? Journal Watch (General), November 7, 2006; 2006(1107): 6 - 6. [Full Text]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
